Status:
COMPLETED
Study of hA20 (Humanized Anti-CD20) in Patients With CD20+ Non-Hodgkin's Lymphoma
Lead Sponsor:
Gilead Sciences
Conditions:
Non-Hodgkin's Lymphoma
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
This is a Phase I trial to look at safety and how a patient's body will tolerate the treatment at different dosages.
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- CD20+ B-cell non-Hodgkin's lymphoma (NHL) with measurable disease
Exclusion
Key Trial Info
Start Date :
September 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2007
Estimated Enrollment :
82 Patients enrolled
Trial Details
Trial ID
NCT00285428
Start Date
September 1 2004
End Date
October 1 2007
Last Update
August 17 2021
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
New York Presbyterian Hospital/Cornell Medical Center
New York, New York, United States, 10021
2
University Hospital of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104
3
MD Anderson Cancer Center
Houston, Texas, United States, 77030